Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise
Executive Summary
Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category
You may also be interested in...
Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta
Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta
Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review
Inhaled insulin manufacturers are emphasizing smaller devices and easier dosing of their products following the review of Pfizer/Sanofi-Aventis' Exubera by FDA's Endocrinologic & Metabolic Drugs Advisory Committee